TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics

SOUTH SAN FRANCISCO, January 27, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing precision immunoregulatory medicines based on tissue Treg biology, today announced the close of an oversubscribed $50 million financing. The financing included funding from new investors Janus Henderson Investors, Balyasny Asset Management L.P.